Organogenesis Holdings Inc (ORGO)
4.00
-0.43
(-9.71%)
USD |
NASDAQ |
Nov 14, 16:00
4.00
0.00 (0.00%)
After-Hours: 16:47
Organogenesis Holdings Debt to Equity Ratio: 0.2409 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.2409 |
| March 31, 2024 | 0.2333 |
| December 31, 2023 | 0.2377 |
| September 30, 2023 | 0.2442 |
| June 30, 2023 | 0.2542 |
| March 31, 2023 | 0.265 |
| December 31, 2022 | 0.2664 |
| September 30, 2022 | 0.2832 |
| June 30, 2022 | 0.2853 |
| March 31, 2022 | 0.3001 |
| December 31, 2021 | 0.3042 |
| September 30, 2021 | 0.3904 |
| June 30, 2021 | 0.3901 |
| March 31, 2021 | 0.4434 |
| December 31, 2020 | 0.4916 |
| September 30, 2020 | 1.512 |
| Date | Value |
|---|---|
| June 30, 2020 | 2.768 |
| March 31, 2020 | 2.310 |
| December 31, 2019 | 1.495 |
| September 30, 2019 | 6.487 |
| June 30, 2019 | 3.153 |
| March 31, 2019 | 2.169 |
| December 31, 2018 | 0.8845 |
| September 30, 2018 | 0.0023 |
| June 30, 2018 | 0.0016 |
| March 31, 2018 | 0.001 |
| December 31, 2017 | -9.886 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.2333
Minimum
Mar 2024
2.768
Maximum
Jun 2020
0.6692
Average
0.3001
Median
Mar 2022
Debt to Equity Ratio Benchmarks
| Poseida Therapeutics Inc | 0.9668 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | 0.0461 |
| Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 443.16M |
| Total Liabilities (Quarterly) | 179.66M |
| Shareholders Equity (Quarterly) | 263.50M |
| Current Ratio | 2.732 |
| Net Debt Paydown Yield | 0.34% |